

# EPIAXIS

## THERAPEUTICS



A NOVEL EPIGENETICALLY DIRECTED IMMUNO-  
ONCOLOGY APPROACH TO PROLONG REMISSION

**J S Crisp CEO**

October 2017

[www.epiaxistherapeutics.com](http://www.epiaxistherapeutics.com)

# Overview



- **Epigenetically directed IO Co.**
- Primary target is **LSD1**
- Abate the **CTC & CSC** burden
- Initial disease indication is **mBC**
- **Novel assets**
- In the **Clinic**

# Three Highlights

---

- 1. Novel FIC inhibitors blocking nuclear entry of LSD1p**
  - Independent & superior to catalytic inhibitors
  - Highly specific to the NLS region
- 2. Novel IO axis**
  - Reprogramming of the CSC epigenome
  - Offers innate and adaptive immunity within the TME
- 3. Open Phase 1b (AD) POC program in mBC**
  - FPI August 2017

# Key Hypothesis

**COMBINATION OF OUR NOVEL EPIGENETIC  
INHIBITORS WITH SOC**



**TO PROLONG REMISSION**

# Phase 1b

OPEN

- **Epi-PRIMED** for **Prolonging Remission in Metastatic Disease**
- PoC cohort dose escalation of **Phenelzine Sulfate with Abraxane<sup>®</sup>** in 13 mBC patients
- 1<sup>st</sup> objective: **safety** of the **OBD** & or **MTD**
- 2<sup>nd</sup> objective: experimental **efficacy** measures
  - CTC/CSC, Th1, Th2, cytokines & PDL1/PD1

# Key Phase 1 Features

---

- 1. First as a epigenetic combination** with SoC Abraxane
- 2. Tracking CTC burden** by numeration & quantification of the **stem & mesenchymal signatures**
  - At protein and transcriptome levels
- 3. Overlaying** CTC burden with standard clinical analysis
- 4. Enumeration** of **T cell** subsets & cytokine profiles
- 5. Quantification** of **LSD1** nuclear entry


# What's Next

---

1. Complete **Phase 1b**
2. Expand **combinations** to include PDL1, CDK , PARP or PI3K inhibitors
3. Expand our **clinical focus** to include lung, ovarian, pancreatic & colon cancers
4. Nominate our **lead** mBC candidate
5. Seeking **licensing** interest now
6. **Capital raising** in 2018



# Conclusion



**PROLONGING  
REMISSION**

- Clinically staged **IO** company
- **Prolong remission** & ultimately prevent metastatic disease
- **Novel** inhibitors against novel targets
- Effective against the **primary tumour** & the **CTC/CSC** burden
- Synergistic with **SoC**
- A great **team** & strong **IP**



---

## Thank you

Dr J S Crisp, CEO

[j.chrisp@epiaxistherapeutics.com](mailto:j.chrisp@epiaxistherapeutics.com)

+61 421 012 268

[www.epiaxistherapeutics.com](http://www.epiaxistherapeutics.com)